Expanding the repertoire reveals recurrent, cryptic and hematopoietic HLA class I minor histocompatibility antigens
Kyra J Fuchs,Marian van de Meent,Maria W Honders,Indu Khatri,Michel G D Kester,Eva A S Koster,Georgia Koutsoumpli,Arnoud H de Ru,Cornelis A M Van Bergen,Peter A van Veelen,Peter A C 't Hoen,Peter van Balen,Erik B van den Akker,Hendrik Veelken,Constantijn Jm Jm Halkes,J H Frederik Falkenburg,Marieke Griffioen,Kyra J. Fuchs,Maria W. Honders,Michel G.D. Kester,Eva A.S. Koster,Arnoud H. de Ru,Cornelis A.M. Van Bergen,Peter A. van Veelen,Peter A.C. 't Hoen,Constantijn JM JM Halkes,J.H. Frederik Falkenburg
DOI: https://doi.org/10.1182/blood.2023022343
IF: 20.3
2024-03-03
Blood
Abstract:Expanding the HLA-I-restricted MiHA repertoire by 81 new antigens reveals that MiHAs are often recurrently targeted in multiple patients. Of all 159 MiHAs, 37 antigens are cryptic, and 11 are new potential targets for immunotherapy due to selective hematopoietic expression. Allogeneic stem cell transplantation (alloSCT) is a curative treatment for hematological malignancies. After HLA-matched alloSCT, anti-tumor immunity is caused by donor T cells recognizing polymorphic peptides, designated minor histocompatibility antigens (MiHAs), that are presented by HLA on malignant patient cells. However, T cells often target MiHAs on healthy non-hematopoietic tissues of patients, thereby inducing side effects known as Graft-versus-Host Disease. Here, we aimed to identify the dominant repertoire of HLA-I-restricted MiHAs to enable strategies to predict, monitor or modulate immune responses after alloSCT. To systematically identify novel MiHAs by genome-wide association screening, T-cell clones were isolated from 39 transplanted patients and tested for reactivity against 191 EBV-B cell lines of the 1000 Genomes Project. By discovering 81 new MiHAs, we more than doubled the antigen repertoire to 159 MiHAs and demonstrated that, despite many genetic differences between patients and donors, often the same MiHAs are targeted in multiple patients. Furthermore, we showed that one quarter of the antigens are cryptic, i.e. translated from unconventional open reading frames, for example long non-coding RNAs, showing that these antigen types are relevant targets in natural immune responses. Finally, using single cell RNA-seq data, we analyzed tissue expression of MiHA-encoding genes to explore their potential role in clinical outcome, and characterized 11 new hematopoietic-restricted MiHAs as potential targets for immunotherapy. In conclusion, we expanded the repertoire of HLA-I-restricted MiHAs and identified recurrent, cryptic and hematopoietic-restricted antigens, which are fundamental to predict, follow or manipulate immune responses to improve clinical outcome after alloSCT.
hematology